Determining the molecular basis for the relationship between IT efficacy and toxicity
- Collaborators: Ben Fairfax, Mark Middleton, Benoît Van den Eynde, Adrian Hill, Paresh Vyas, Ronjon Chakreverty
- Challenge: Minimising immuno-oncology toxicity
Checkpoint inhibitor, T-cell redirector efficacy and irAEs are characterised by T-cell clonal expansion. Oxford researchers are investigating T cell specificity in treated patients to identify on-target and off-cancer reactivities. This knowledge can be used to modify clinical decision making and facilitate vaccine candidature with minimal on target off cancer effects. Similar approaches will underpin pioneering work in stem cell transplantation treatment of myeloid leukaemia by identifying T-cell Receptors that recognise Graft vs Leukemia but not Graft vs Host Disease epitopes with a view to developing epitope-driven pre-transplant conditioning regimes.